StockMarketWire.com - AstraZeneca has presented positive results from its phase III OlympiAD trial that showed a statistically-significant and clinically-meaningful improvement in progression-free survival for patients treated with Lynparza (olaparib) tablets (300mg twice daily), compared to treatment with physician's choice of a standard of care chemotherapy.

In addition to meeting its primary endpoint of PFS assessed by blinded independent central review (BICR), the trial showed that patients treated with Lynparza had a 42% reduction in risk of their disease worsening or death (HR 0.58; 95% CI 0.43-0.80; p=0.0009; median 7.0 vs 4.2 months) compared to those who received chemotherapy (capecitabine, vinorelbine, eribulin).

The data were presented at the 2017 ASCO annual meeting in Chicago.

The trial was designated for the .Best of ASCO. selection, underscoring the importance of these results for patients and physicians, and the results are published in the New England Journal of Medicine.

Executive vice-president, global medicines development and chief medical officer at AstraZeneca, Sean Bohen, said: "The OlympiAD results shared today mark the first time a targeted therapy shows benefit over the current standard of care for patients with HER2-negative gBRCA-mutated metastatic breast cancer.

"This also represents an important milestone for Lynparza as this is the first positive Phase III trial in which a PARP inhibitor has shown a significant benefit for patients outside of ovarian cancer."




Story provided by StockMarketWire.com